Sensei Biotherapeutics (NASDAQ:FTH) Announces Earnings Results, Beats Estimates By $4.42 EPS

Sensei Biotherapeutics (NASDAQ:FTH) released its earnings results on Tuesday. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($5.04) by $4.42, FiscalAI reports.

Sensei Biotherapeutics Stock Performance

FTH stock traded down $1.84 during midday trading on Tuesday, reaching $25.50. The company’s stock had a trading volume of 18,518 shares, compared to its average volume of 198,655. Sensei Biotherapeutics has a 52 week low of $7.20 and a 52 week high of $37.90. The stock has a market cap of $34.21 million, a PE ratio of -0.18 and a beta of -0.26.

Insider Activity at Sensei Biotherapeutics

In other news, major shareholder James Peyer sold 25,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares of the company’s stock, valued at $2,605,442.84. This represents a 16.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the transaction, the chief executive officer directly owned 764,234 shares in the company, valued at $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC lifted its position in Sensei Biotherapeutics, Inc. (NASDAQ:FTH) by 10.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,516 shares of the company’s stock after buying an additional 1,100 shares during the period. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on FTH shares. Oppenheimer began coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price target for the company. Citigroup started coverage on Sensei Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $55.00 target price for the company. Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Finally, Leerink Partners assumed coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $54.89.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.